metricas
covid
Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Chylous Fistula Following Axillary Lymphadenectomy
Journal Information
Vol. 92. Issue 1.
Pages 55-56 (January 2014)
Vol. 92. Issue 1.
Pages 55-56 (January 2014)
Scientific letter
Full text access
Chylous Fistula Following Axillary Lymphadenectomy
Fístula quilosa poslinfadenectomía axilar
Visits
4719
Erene V. Flores
Corresponding author
rne227@yahoo.com

Corresponding author.
, Gonzalo de Castro, Enrique Casal, Constantino Sobrino
Unidad de Senología y Patología Mamaria, Servicio de Cirugía General y del Aparato Digestivo, Hospital Xeral–Cíes, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Full Text

Axillary lymph node dissection is one of the pillars of locoregional breast cancer treatment. Its possible complications include seroma, lymphorrhea, lymphocele, chronic lymphedema and sensory alterations on the underside of the arm.1 Chylous fistula is a complication that presents in thoracic, abdominal and neck surgery, but it is rare in axillary clearance. These complications can delay the start of adjuvant therapy. We present a case report of a chylous fistula after axillary lymphadenectomy due to breast cancer. We also performed a search of the literature related to the clinical presentation and treatment of this entity.

The patient is a 55-year-old woman with a history of iodine allergy, hypertension, type II diabetes mellitus and liver transplantation due to cirrhosis of the liver 10 years earlier. A tumor in the upper half of the left breast and hemorrhage through an orifice in the nipple had been detected.

A mammogram showed small breast asymmetry with increased density of the left breast at the level of the upper outer quadrant, which had multiple fatty areas and was not accompanied by distortion of the tracts or clustered microcalcifications. Ultrasound detected no clear alterations. Magnetic resonance imaging revealed findings consistent with a malignant lesion affecting the upper quadrants of the left breast (probably lobular carcinoma) and axillary lymphadenopathies of a pathological size. Core needle biopsy (CNB) of the left breast was positive for grade II infiltrating ductal carcinoma and ductal carcinoma in situ without vascular invasion. Immunohistochemical study revealed estrogen receptor (−), progesterone receptor (−), Ki67: 65% and 45 Her2/neu (c-erbB2): 1+. The extension study was completed with thoracic computed tomography (CT) and bone scan, which showed no metastasis. The case was submitted to the Committee on Breast Cancer, at which time it was decided to perform surgery with adjuvant treatment. The left mastectomy technique described by Madden was used with left axillary lymph node dissection of levels I and II. The pathology study revealed: multicentric infiltrating ductal carcinoma, Nottingham grade 3 (T2, P3, M3), with an approximate size of 10cm×10cm; high-grade intraductal carcinoma with intratumoral comedo-necrosis; neoplastic infiltration in 6 of the 12 isolated lymph nodes; lymphovascular invasion; pathological stage pT3 pN2a. Surgical resection margins were free of neoplastic involvement. Immunohistochemical study showed estrogen receptor (−), progesterone receptor (−) Her 2neu 45 (−) and Ki67: 24%.

On the second day of the postoperative period, the discharge through the axillary drain was 230mL, and from the fifth day its characteristics were suggestive of chylous effusion (Fig. 1). The analysis of the extracted liquid showed that it contained 2751mg/dL of triglycerides. After initiating a fat-free diet, it was possible to reduce the discharge to 90mL/day and modify the characteristics of the liquid, which allowed us to withdraw the drain 20 days post-op and discharge the patient (Fig. 2). At the 3-month follow-up office visit, no seroma or other complications were observed, and the patient was able to start adjuvant treatment with radiotherapy and chemotherapy.

Fig. 1.

Lactescent appearance of the liquid accumulated in the axillary drain device.

(0.11MB).
Fig. 2.

Chart showing the evolution of the discharge and characteristics of the axillary drain liquid.

(0.09MB).

Chylous fistula is a rare complication of axillary lymph node dissection, with some 10 cases having been described in the literature.2,3 It can be caused by injury to the aberrant lymphatic vessels associated with the thoracic duct. Anatomical studies have demonstrated that in over 30% of cases the thoracic duct divides into branches and up to 4% empty into the venous system through these multiple branches4; in these cases, 1% empty into the higher and medial portions of the axillary vein. These anatomical variations make the problem more prevalent in lymph node dissection on the left side. Usually, lymphadenectomy is performed outside the area where the thoracic duct and the venous system connect.

Diagnosis is made by the presence of suspiciously high discharge through the postoperative axillary drains (more than 500mL/day) or with the presentation of a thick lactescent effusion. It is confirmed by triglyceride content (>110mg/dL) and/or a high percentage of chylomicrons. It is estimated that triglyceride levels above 110mg/dL are diagnostic of chylous fistula, while values between 50 and 110mg/dL require determination of chylomicrons to confirm the diagnosis.5 As complementary diagnostic tests, lymphoscintigraphy and lymphography are recommended, which are used to assess the injury to the thoracic duct.6

During axillary lymph node dissection, especially on the left side, care should be taken not to injure the lymphatic ducts in the deepest part of the axillary space. However, if the chylous fistula is found during surgery, these should be ligated. If it occurs in the immediate postoperative period, treatment should be conservative.2,7,8 When the liquid through the drain tube acquires a chylous appearance after the start of food intake, it is recommended to establish a fat-free diet and, for the most persistent cases, peripheral or enteral nutrition is recommended with medium-chain media triglycerides.9 The use of digestive secretion inhibitors (somatostatin, octreotide) may also be considered as they are applied in the treatment of chylothorax.10 Surgery should only be considered in exceptional cases in order to ligate the vessels causing the effusion.5

References
[1]
K. Taylor.
Morbidity associated with axillary surgery for breast cancer.
ANZ J Surg, 74 (2004), pp. 314-317
[2]
M.I. Gottlieb, J. Greenfield.
Variations in the terminal portion of the human thoracic duct.
AMA Arch Surg, 73 (1956), pp. 955-959
[3]
A. Piñero, P. Galindo, J. Illana, P. Parrilla.
Fístula quilosa postlinfadenectomía axilar.
Rev Senología Patol Mam, 20 (2007), pp. 29-32
[4]
A. Abdelrazeq.
Lumphoscintigraphic demonstration of chylous leak after axillary lymph node dissection.
Clin Nucl Med, 30 (2005), pp. 299-301
[5]
E. Nakajima, H. Iwata, T. Iwase, H. Murai, M. Mituhiro, S. Miura, et al.
Four cases of chylous fistula after breast cancer resection.
Breast Cancer Res Treat, 83 (2004), pp. 11-14
[6]
A. Harlak, S. Karahatay, O. Onguru, O. Mentes, M. Gerek, T. Chyle.
Fistula after neck dissection for an unusual breast cancer recurrence.
Breast Care, 3 (2008), pp. 274-276
[7]
M. Cong, Q. Liu, W. Zhou, J. Zhu, C. Song, X. Tian.
Six cases of chylous leakage after axillary lymph node dissection.
Onkologie, 31 (2008), pp. 321-324
[8]
G. Sakman, C. Parsak, O. Demircan.
A rare complication in breast cancer surgery: chylous fistula and its treatment.
Acta Chir Belg, 107 (2007), pp. 317-319
[9]
M. Younus, R. Chang.
Chyle fistulae: treatment with total parenteral nutrition.
J Laryngol Otol, 102 (1988), pp. 384
[10]
A. Gómez-Caro, C. Marrón, F. Moradiellos, V. Díaz-Hellín, J. Pérez, J.L. Martín de Nicolás.
Octreotide for conservative management of postoperative chylotorax.
Arch Broconeumol, 40 (2004), pp. 473-475

Please cite this article as: Flores EV, de Castro G, Casal E, Sobrino C. Fístula quilosa poslinfadenectomía axilar. Cir Esp. 2014;94:55–56.

Copyright © 2012. AEC
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos